Ascendis Pharma A (ASND) Cash & Equivalents (2012 - 2026)

Ascendis Pharma A has disclosed Cash & Equivalents across 15 years of filings, most recently posting $670.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $670.6 million, up 23.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $670.6 million (up 23.1% YoY), and the FY2025 annual result was $717.1 million, up 19.93% from the prior year.
• Cash & Equivalents came in at $670.6 million for Q1 2026 at Ascendis Pharma A, down from $717.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $848.1 million in Q1 2022 to a low of $278.6 million in Q2 2024.
• The 5-year median for Cash & Equivalents is $559.2 million (2025), against an average of $560.9 million.
• Across the five-year window, Cash & Equivalents slumped 40.17% in 2023 and jumped 100.74% in 2025, its largest moves.
• Ascendis Pharma A's Cash & Equivalents stood at $453.8 million in 2022, then slipped by 7.01% to $421.9 million in 2023, then surged by 41.71% to $597.9 million in 2024, then advanced by 19.93% to $717.1 million in 2025, then decreased by 6.48% to $670.6 million in 2026.
• The last three Cash & Equivalents figures came in at $670.6 million (Q1 2026), $717.1 million (Q4 2025), and $630.2 million (Q3 2025), per Business Quant data.